These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 29110851)

  • 1. Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping.
    Zhang Y; Yin J; Peng F
    Lung Cancer; 2017 Nov; 113():69-71. PubMed ID: 29110851
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primary EGFR mutation plus secondary MET amplification and a novel acquired crizotinib-resistant mutation MET G1108C.
    Li YQ; Song SS; Jiang SH; Zhang XY
    Ann Oncol; 2017 Oct; 28(10):2622-2624. PubMed ID: 28961830
    [No Abstract]   [Full Text] [Related]  

  • 3. Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations.
    Dong HJ; Li P; Wu CL; Zhou XY; Lu HJ; Zhou T
    Lung Cancer; 2016 Dec; 102():118-121. PubMed ID: 27987579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series.
    Chiari R; Buttitta F; Iacono D; Bennati C; Metro G; Di Lorito A; Iezzi M; Tiseo M; Mazzoni F; Cappuzzo F; Marchetti A; Crinò L
    Clin Lung Cancer; 2014 Nov; 15(6):470-4. PubMed ID: 25087901
    [No Abstract]   [Full Text] [Related]  

  • 5. Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma.
    Shea M; Huberman MS; Costa DB
    J Thorac Oncol; 2016 Jul; 11(7):e81-2. PubMed ID: 26845194
    [No Abstract]   [Full Text] [Related]  

  • 6. Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.
    Benderra MA; Aspeslagh S; Postel-Vinay S; Bigot L; De Baere T; Loriot Y; Lacroix L; Massard C; Vassal G; André F; Soria JC
    J Thorac Oncol; 2016 Feb; 11(2):e21-3. PubMed ID: 26845121
    [No Abstract]   [Full Text] [Related]  

  • 7. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
    J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib.
    Mahjoubi L; Gazzah A; Besse B; Lacroix L; Soria JC
    Invest New Drugs; 2016 Jun; 34(3):397-8. PubMed ID: 26892698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK translocation.
    Chun SG; Iyengar P; Gerber DE; Hogan RN; Timmerman RD
    J Clin Oncol; 2015 Feb; 33(5):e25-6. PubMed ID: 24616318
    [No Abstract]   [Full Text] [Related]  

  • 10. Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.
    Jenkins RW; Oxnard GR; Elkin S; Sullivan EK; Carter JL; Barbie DA
    Clin Lung Cancer; 2015 Sep; 16(5):e101-4. PubMed ID: 25769807
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel MET Exon 14 Skipping Treatment-Naïve Lung Adenocarcinoma Presented Primary Resistance to Crizotinib.
    Jiang W; Yang N; Zhang Y
    J Thorac Oncol; 2018 Jul; 13(7):e124-e126. PubMed ID: 29935852
    [No Abstract]   [Full Text] [Related]  

  • 12. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Heist RS; Sequist LV; Borger D; Gainor JF; Arellano RS; Le LP; Dias-Santagata D; Clark JW; Engelman JA; Shaw AT; Iafrate AJ
    J Thorac Oncol; 2016 Aug; 11(8):1242-1245. PubMed ID: 27343442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.
    Caparica R; Yen CT; Coudry R; Ou SI; Varella-Garcia M; Camidge DR; de Castro G
    J Thorac Oncol; 2017 Jan; 12(1):141-144. PubMed ID: 27664533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete response to crizotinib in a patient with adenocarcinoma of the lung cancer harboring c- MET amplification.
    Cil I; Zirtiloglu A; Saydam N; Tural D
    J BUON; 2017; 22(1):279-280. PubMed ID: 28365967
    [No Abstract]   [Full Text] [Related]  

  • 15. Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.
    Jin W; Shan B; Liu H; Zhou S; Li W; Pan J; Lin L; Hu D; Pan Y
    J Thorac Oncol; 2019 Jul; 14(7):e137-e139. PubMed ID: 31055074
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful crizotinib retreatment after crizotinib-induced interstitial lung disease.
    Yanagisawa S; Inoue A; Koarai A; Ono M; Tamai T; Ichinose M
    J Thorac Oncol; 2013 Aug; 8(8):e73-4. PubMed ID: 23857405
    [No Abstract]   [Full Text] [Related]  

  • 17. Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.
    Qin RY; Liu LS; Zhang HY; Lu CH; Guo XY; Zhang LY; Yuan XB; Xue HH
    Medicine (Baltimore); 2021 Jan; 100(4):e24300. PubMed ID: 33530219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interest of crizotinib in a lung cancer patient with de novo amplification of MET].
    Rabeau A; Rouquette I; Vantelon JM; Taranchon-Clermont E; Mazières J
    Rev Mal Respir; 2017 Jan; 34(1):57-60. PubMed ID: 27745897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Widespread renal polycystosis induced by crizotinib.
    Di Girolamo M; Paris I; Carbonetti F; Onesti EC; Socciarelli F; Marchetti P
    Tumori; 2015 Jul; 101(4):e128-31. PubMed ID: 25953441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.
    Le X; Freed JA; VanderLaan PA; Huberman MS; Rangachari D; Jorge SE; Lucena-Araujo AR; Kobayashi SS; Balasubramanian S; He J; Chudnovsky Y; Miller VA; Ali SM; Costa DB
    Clin Lung Cancer; 2015 Sep; 16(5):e105-9. PubMed ID: 25922291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.